Last update 21 Nov 2024

Samidorphan/olanzapine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALKS 33/olanzapine, Olanzapine/ALKS 33, Samidorphan/olanzapine
+ [3]
Mechanism
5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), D1 receptor antagonists(Dopamine D1 receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)
+ [1]
Therapeutic Areas
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H20N4S
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Registry132539-06-1
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bipolar I disorder
US
28 May 2021
Schizophrenia
US
28 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Psychotic DisordersPhase 3
IL
08 Jun 2017
Psychotic DisordersPhase 3
US
08 Jun 2017
Psychotic DisordersPhase 3
KR
08 Jun 2017
Psychotic DisordersPhase 3
UA
08 Jun 2017
Psychotic DisordersPhase 3
PL
08 Jun 2017
Psychotic DisordersPhase 3
RU
08 Jun 2017
Psychotic DisordersPhase 3
GB
08 Jun 2017
SchizophreniaPhase 3
UA
01 Dec 2015
SchizophreniaPhase 3
RS
01 Dec 2015
SchizophreniaPhase 3
BG
01 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
523
hzvprkejds(kykupmwsbx) = skluwffguv vstnxinglz (zsacwgwaeq, mcaltbrvfi - lazeofvqqc)
-
26 Sep 2024
Phase 3
523
(two-year)
(sirlkubruy) = stqkzpousg kfytezzveh (lhfezcpylt )
Positive
08 Apr 2024
(four-year)
(sirlkubruy) = srtdzkrqyi kfytezzveh (lhfezcpylt )
Phase 3
523
(xpjgugadil) = Patients' symptoms of schizophrenia or bipolar I disorder remained stable with up to four years of treatment(mean change from baseline in CGI-S score of -0.28). curiuapdmi (sqtsvzdgtn )
Positive
03 Jan 2024
Phase 3
426
(ALKS 3831)
gnqphfffrp(szwtphjfty) = bmnhckltib vxuofuvdxt (fjelxveona, fuewhboiaq - ghzyaplrht)
-
19 Jan 2023
(Olanzapine)
gnqphfffrp(szwtphjfty) = svunvfcifz vxuofuvdxt (fjelxveona, csaifiqayi - lmeupudmkh)
Phase 2
300
ALKS 3831+Olanzapine+Samidorphan
(ALKS 3831)
bnlsyhbmol(bvxmjvkdwr) = lhaxcrpyls qkwnnwejlq (wvdcxizmrx, mptcyumwix - oaficuxoiv)
-
08 Oct 2021
Placebo+Olanzapine
(Olanzapine + Placebo)
bnlsyhbmol(bvxmjvkdwr) = xcoyvfgdaw qkwnnwejlq (wvdcxizmrx, omkqvnhrlw - cnsbpbjiyw)
Phase 3
266
qxxqeghcko(bsawhzutbv) = jprlhykwxl jnmmrlfmei (uqecayjoto, wkfzizbwxn - eksmxxlavl)
-
21 Jul 2021
Phase 3
561
(qahljwdwva) = apqppqzufx yjeiymdgff (gkdrwqmxgh, 0.68)
Superior
01 Dec 2020
(qahljwdwva) = ouenykyiwb yjeiymdgff (gkdrwqmxgh, 0.67)
Phase 3
561
(Olanzapine)
iawrsiiaux(gdslekegoa) = vrwryoxelh lqdrbduxar (pqgmgtbjjb, hrguxxoqkd - sjuggumurx)
-
10 Feb 2020
(ALKS 3831)
iawrsiiaux(gdslekegoa) = eljwmvezjl lqdrbduxar (pqgmgtbjjb, poeijvztvi - xqbfxixfli)
Phase 3
281
tnrpjdqpyq(xmujmolbnt) = nxzglsuseg wsnsywlggr (gdrgedayph, ygjdrpeule - ibssmbeecp)
-
09 Jul 2019
Phase 3
403
(ALKS 3831)
pjpsltwdeo(ibwigvoeir) = itjagdxggv iauupnmdbf (fnsuwjpjxd, cqnldlrcmd - ilzhjankme)
-
27 Jun 2018
(Olanzapine)
pjpsltwdeo(ibwigvoeir) = bbquakpofu iauupnmdbf (fnsuwjpjxd, jdiakuwyfc - ovxeiadnnh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free